Mantle cell lymphoma is a unique entity of CD5 +, CD23 − B-cell lymphoma characterized by dysregulation of cyclin D1 by the translocation t(11;14). Despite its dependence on cyclin D1 ...

High-dose chemotherapy and HSCT can provide long-term benefits in patients with MCL, a retrospective study suggests.

Galapagos reported promising results from ATALANTA-1 study show 100% ORR/CR for relapsed Mantle Cell Lymphoma. Click for GLPG ...

Roche has secured approval from the EC for Columvi plus GemOx combo to treat adults with R/R diffuse large B-cell lymphoma (DLBCL).

China’s National Medical Products Administration (NMPA) has approved InnoCare Pharma’s Bruton's tyrosine kinase (BTK) ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

Q1 2025 Management View CEO Chad Robins highlighted a strong start to the year, with MRD revenue increasing 34% year-over-year, driven by clinical volumes, ASP improvements, and pharma sequencing. The ...

follicular lymphoma marginal zone lymphoma mantle cell lymphoma anemia that’s caused by myelodysplastic syndrome multiple myeloma Revlimid belongs to a class of drugs called thalidomide analogues.

is in development for CD5-positive hematologic malignancies including T-cell lymphoma, T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia and mantle cell lymphoma. T-cell lymphomas, as ...

Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and ...